Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-01
2010-11-02
Aulakh, Charanjit S (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S292000, C514S284000
Reexamination Certificate
active
07825129
ABSTRACT:
The present invention relates to compounds for the inhibition of poly(ADP-ribose) polymerase (PARP). In some embodiments, the compounds have the Formula:wherein the constituent variables are as defined herein. The invention further provides methods for the use of the compounds disclosed herein.
REFERENCES:
patent: 4113731 (1978-09-01), Winters et al.
patent: 4263304 (1981-04-01), Ishizumi et al.
patent: 6358975 (2002-03-01), Eliasson et al.
patent: 6989388 (2006-01-01), Pellicciari et al.
patent: WO 99/11645 (1999-11-01), None
patent: WO 99/59975 (1999-11-01), None
S. Kano et al., “A facile synthesis of 4-phenylcarbostyrils and 4-phenylisocarbostyril involving photocyclization of . . . ”, Heterocycles, 12(4), pp. 489-492.
Cuzzocrea,S., et al., “Beneficial effects of 3-aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase ina rat model of splanchnic artery occlusion and reperfusion”,Br. J. Pharmacol., 121:1065-1074, 1997.
Liaudet, L., et al., “Poly (ADP-ribose) synthetase mediates intestinal mucosal barrier dysfunction after mesenteric ischemia.”,Shock, 14:134-141, 2000.
Cuzzocrea, S.,et al., Effects of n-acetylcysteine in a rat model of ischemia and reperfusion injury,Cardiovasc. Res., 47:537-548, 2000.
Cuzzocrea, S., et al., Beneficial effects of tempol, a membrane-permeable radical scavenger, in a rodent model of splanchnic artery occlusion and reperfusion.,Shock, 14:150-156, 2000.
Chiang and Lam, “Post-Treatment at 12 or 18 Hours with 3-Aminobenzamide Ameliorates Retinal Ischemia-Reperfusion Damage”,Invest. Ophthalmol. Vis. Sci., 41(10):3210-3214, 2000.
Chatterjee, P.K., et al., “Inhibitors of poly (ADP-ribose) synthetase protect rat proximal tubular cells against oxidant stress,”Kidney Int., 56:973-984, 1999.
Jung, et al., “Protection against Hydrogen Perioxide Induced Injury in Renal Proximal Tubule Cell Lines by Inhibition of Poly(ADP-Riboes) Synthase”,Kidney Blood Press. Res., 23:14-19,, 2000.
Min, et al., “Role of Lipid Peroxidation and Poly(ADP-ribose) Polymerase Activation in Oxidant-Induced Membrane Transport Dysfunction in Opossum Kidney Cells”,Toxicol. Appl. Pharmacol., 166:196-202, 2000.
Filipovic, D., et al., “Inhibition of PARP prevents oxidant-induced necrosis but not apoptosis in LLC-PK1 cells”,Am. J. Physiol., 277-F428-F436, 1999.
Cuzzocrea, S., et al., Role of free radicals and poly(ADP-ribose) synthetase in intestinal tight junction permeability.,Mol. Med., 6:766-778, 2000.
Tikoo, K., et al.., “Histone H3 phosphorylation is coupled to poly-(ADP-ribosylation) during reactive oxygen species-induced cell death in renal proximal tubular epithelial cells”,Mol. Pharmacol. , 60:394-402, 2001.
Martin, D., et al., “Inhibition of poly(ADP-ribose) polymerase attenuates ischemic renal injury in rats”,Am. J. Physiol. Regulatory Integrative Comp. Physiol., 279:R1834-R1840, 2000.
Chatterjee, P.K., et al., “Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat”,Kidney Int. , 58:658-673, 2000.
Zingarelli, B., et al., “Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase”,Cardiovasc. Res., 36:205-215, 1977.
Thiemermann, C.,et al.,“Inhibition of the activity of poly(ADP ribose) synthetase reduced ischemia-reperfusion injury in the heart and skeletal muscle”,Proc. Natl. Acad. Sci. USA, 94:679-683, 1997.
Chen, C-F., et al., “The Protective Effect of Niacinamide on Ischemia-Reperfusion-Induced Liver Injury”J. Biomed. Sci., 8:446-452, 2001.
Tabuchi, K., et al., “Poly(adenosine diphosphate-ribose) synthetase inhibitor 3-aminobenzamide alleviates cochlear dysfunction induced by transient ischemia”,Ann. Otol. Rhinol. Laryngol., 110:118-121, 2001.
Szabo, C., et al., “Inhibition of poly (ADP-ribose)Synthetase Attenuates Neutrophil Recruitment and Exerts Antiinflammatory Effects”,J Exp. Med., 186(7):1041-1049, 1997.
Miesel, et al., “Modulation of Inflammatory Arthritis by Inhibition of Poly(ADP ribose) Polymerase”,Inflammation, 19:379-387, 1995.
Jijon, et al., “Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis”,Am. J. Physiol. Gastrointest. Liver Physiol. , 279:G641-G651, 2000.
Scott, G., et al., “Role of poly(ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis”,J. Neuroimmunology, 117(1-2):78-86, 2001.
Wallis, R.A., et al., “Neuroprotection against nitric oxide injury with inhibitors of ADP-ribosylation”,Neuroreport, 5:245-248, 1993.
Whalen, et al., “Traumatic Brain Injury in Mice Deficient in Poly-ADP(Ribose) Polymerase:A Prelimimary Report”,Acia Neurochir. Suppl., 76:61-64, 1999.
Whalen, et al.,“Reduction of Cognitive and Motor Deficits After Traumatic Brain Injury in Mice Deficieitn in Poly(ADP-Ribose) Polymerase”,J. Cereb. Blood Flow Metab., 19:835-842, 2000.
LaPlaca, M.L., et al., “Pharmacologic inhibition of poly(ADP-ribose) polymerase is neuroprotective following traumatic brain injury in rats”,J. Neurotrauma, 18:369-376, 2001.
Lam, et al., “The Effect of 3-Aminobenzamide, An Inhibitor of Poly-ADP-Ribose Polymerase, on Ischemia/Reperfusion Damage in Rat Retina”,Res. Commun. Mol. Pathol. Pharmacol., 95:241-252, 1997.
Durrant, L.G., et al., “Potentiation of Cell Killing by Inhibitors of Poly (ADP-Ribose) Polymerase in Four Rodent Cell Lines Exposed to N-Methyl-N-Nitrosourea or UV Light”,Chem. Biol. Interact., 38:325-338, 1982.
Horsman, M.R.., et al, “Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase”,Br. J. Cancer, 53: 247-254, 1986.
Bowman, K.J., et al.,“Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro”,Br. J. Cancer., 84(1): 106-112, 2001.
Berry, D..M., et al., “All trans retinoic acid induces apoptosis in acute promyelocytic NB4 cells when combined with isoquinolinediol, a poly(ADP-ribose) polymerase inhibitor”,Leuk. Res. , 24:307-316, 2000.
Boulton, S., et al., “Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors”,Br. J. Cancer, 72:849-856, 1995.
Tentori, L., et al., “Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds”,Leukemia, 13(6):901-909, 1999.
Bowman, K.J., et al., “Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064”,Br. J. Cancer, 78(10):1269-1277, 1998.
Chatterjee, S., et al., “Hypersensitivity to clinically useful alkylating agents and radiation in poly(ADP-ribose) polymerase-deficient cell lines”,Cancer Commun., 2(12):401-407, 1990.
Weltin, D., et al., “Effect of 6(5H)-phenanthridinone, an inhibitor of poly(ADP-ribose) polymerase, on cultured tumor cells”,Oncol., Res., 6:399-403, 1994.
Griffin, et al., “Resistance-Modifying Agents. 5.1Synthesis and Biological Properties of Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase (PARP)”,J. Med. Chem.,41:5247-5256, 1998.
Delaney, et al., “Potentiation of temozolomide and topotecan growth inhibition and cytoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors ina panel of human tumor cell lines”,Clin. Cancer Res., 6:2860-2867, 2000.
Chatterjee, S., et al., “X-ray-induced damage repair in exponentially growing and growth arrested confluent poly(adenosine diphosphate-ribose) polymerase-deficie
Moroni Flavio
Pellicciari Roberto
Aulakh Charanjit S
Elrifi Ivor R.
Erlacher Heidi A.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Thieno[2,3-c] isoquinolines for use as inhibitors of PARP does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thieno[2,3-c] isoquinolines for use as inhibitors of PARP, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thieno[2,3-c] isoquinolines for use as inhibitors of PARP will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4170051